HONG KONG, March 10 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Biodel Inc. (NASDAQ: BIOD) and MannKind Corporation (NASDAQ: MNKD). Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com/Reports.php.
The global pharmaceutical market is expected to experience wide changes, with trends growing towards the Asia-Pacific region. A favorable regulatory environment has started to emerge in India, China, Malaysia, South Korea and Indonesia; drawing the attention of larger API product providers. This new competition within an already fast-paced economy has closed the gap between product cost and disposable income of consumers- a change that is expected to drive long-term growth within the global marketplace. Global pharmaceutical market sales are expected to grow at a 4 - 7% compound annual growth rate (CAGR) through 2013, largely driven via growing access to health-care in emerging economic regions. Short-term growth within the sector will be fueled by the US market, as it remains the largest pharmaceutical market in the world. A large focus on R&D in biotechnology, special drugs and generic drugs will remain a strong catalyst to meet 2011 targets of $315 billion dollar in sales volume within the United States alone.
World Street Fundamentals has highlighted Biodel Inc. for its focus on developing novel forms of insulin and other peptide hormones for use in treating diabetes and its complications, including hyperglycemia, hypoglycemia, cardiovascular complications and weight control. Biodel is building a pipeline of insulin- and other peptide hormone-based product candidates and companion products using proprietary technology, scientific knowledge and clinical expertise in diabetes drug development. To read the report on Biodel Inc. (NASDAQ: BIOD), click here: www.WorldStreetFundamentals.com/ViewFullReport.BIOD.php.
Due to overwhelming requests for information, World Street recognizes MannKind Corporation for its recent trading activity, news of class-action lawsuits and FDA deferral regarding AFREZZA. The company is requested to perform two additional clinical trials with the inhaler, in addition to requirements of additional risk disclosure to patients if approved. To read the report on MannKind Corporation (NASDAQ: MNKD), click here: www.WorldStreetFundamentals.com/ViewFullReport.MNKD.php.
About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world.
SOURCE World Street Fundamentals